Advertisement
Advertisement
U.S. markets open in 4 hours 39 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Athersys, Inc. (ATHX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2699+0.0113 (+4.37%)
At close: 04:00PM EDT
0.2771 +0.01 (+2.67%)
Pre-Market: 04:51AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close0.2586
Open0.2600
Bid0.2726 x 4000
Ask0.2767 x 1000
Day's Range0.2600 - 0.2700
52 Week Range0.1700 - 1.8100
Volume7,723,755
Avg. Volume12,702,446
Market Cap71.236M
Beta (5Y Monthly)-1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3570
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATHX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Athersys, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • American City Business Journals

    Athersys hires turnaround consultant as interim CFO

    Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.

  • Business Wire

    Athersys Appoints Kasey Rosado as Interim Chief Financial Officer

    CLEVELAND, August 04, 2022--Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

  • American City Business Journals

    Athersys shareholders vote to approve reverse stock split

    Athersys leaders want to consolidate the company's shares to raise their trading price and increase the number of shares that could be issued in the future.

Advertisement
Advertisement